BioNTech SE Sponsored ADR $BNTX Shares Sold by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp lowered its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 4.5% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 154,186 shares of the company’s stock after selling 7,214 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned 0.07% of BioNTech worth $15,206,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Financial Consulate Inc. purchased a new position in BioNTech during the third quarter worth approximately $36,000. LRI Investments LLC boosted its position in shares of BioNTech by 234.6% during the 2nd quarter. LRI Investments LLC now owns 445 shares of the company’s stock valued at $47,000 after acquiring an additional 312 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of BioNTech by 118.2% in the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after purchasing an additional 305 shares during the period. Hantz Financial Services Inc. increased its position in BioNTech by 472.0% during the second quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock worth $61,000 after purchasing an additional 472 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in BioNTech by 40.8% during the third quarter. GAMMA Investing LLC now owns 784 shares of the company’s stock worth $77,000 after purchasing an additional 227 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Trading Up 1.1%

BNTX opened at $119.34 on Wednesday. BioNTech SE Sponsored ADR has a 52 week low of $81.20 and a 52 week high of $126.77. The company has a quick ratio of 7.02, a current ratio of 7.12 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $100.04 and a 200-day simple moving average of $103.70. The firm has a market cap of $26.87 billion, a P/E ratio of -45.38 and a beta of 1.40.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.75 by ($0.89). BioNTech had a negative net margin of 17.91% and a negative return on equity of 3.03%. The firm had revenue of $1.78 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter in the prior year, the firm posted $0.81 EPS. BioNTech’s quarterly revenue was up 22.0% compared to the same quarter last year. On average, equities analysts expect that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

Analysts Set New Price Targets

BNTX has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $140.00 price target on shares of BioNTech in a research note on Thursday, December 11th. Jefferies Financial Group reiterated a “buy” rating and issued a $151.00 price objective on shares of BioNTech in a research report on Wednesday, December 3rd. JPMorgan Chase & Co. reduced their target price on BioNTech from $121.00 to $120.00 and set a “neutral” rating on the stock in a research report on Thursday, October 23rd. TD Cowen reaffirmed a “hold” rating on shares of BioNTech in a research note on Monday, November 3rd. Finally, The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $115.00 to $142.00 in a research report on Friday, January 16th. Eleven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $140.03.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.